At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Trading 03-20 14:58:07 EDT
10.85
-0.64
-5.61%
High11.53Low10.81Vol365.99K
Open11.36D1 Closing11.49Amplitude6.22%
Mkt Cap339.34MTradable Cap170.19MTotal Shares31.29M
T/O4.10MT/O Rate2.33%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
TIPRANKS  ·  00:55
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study
TIPRANKS  ·  00:32
Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline
TIPRANKS  ·  00:30
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline
Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital
TIPRANKS  ·  03-20 23:50
Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital
Investor Outlook: Knight Therapeutics beats estimates on product growth
Bloomberg  ·  03-20 23:28
Investor Outlook: Knight Therapeutics beats estimates on product growth
Oppenheimer Adjusts Pelthos Therapeutics Price Target to $62 From $60, Maintains Outperform Rating
MT Newswires Live  ·  03-20 21:42
Oppenheimer Adjusts Pelthos Therapeutics Price Target to $62 From $60, Maintains Outperform Rating
Aquestive Therapeutics Announces Key Legal Leadership Transition
TIPRANKS  ·  03-20 19:57
Aquestive Therapeutics Announces Key Legal Leadership Transition
LENZ Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Reuters  ·  03-20 19:18
LENZ Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Stoke Therapeutics price target raised to $60 from $36 at Canaccord
TIPRANKS  ·  03-20 19:17
Stoke Therapeutics price target raised to $60 from $36 at Canaccord
Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion
Stock News  ·  03-20 19:02
Novartis to Acquire Synnovation Therapeutics Breast Cancer Drug Assets for Up to $3 Billion
Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Dow Jones  ·  03-20 19:00
Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
TIPRANKS  ·  03-20 18:55
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics
TIPRANKS  ·  03-20 18:15
Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
TIPRANKS  ·  03-20 14:00
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway
TIPRANKS  ·  03-20 13:35
Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway
Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Dow Jones  ·  03-20 04:10
Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
GlobeNewswire  ·  03-20 04:03
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Dow Jones  ·  03-20 04:01
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  03-20 02:48
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Larimar Therapeutics: Undervalued First-in-Class Frataxin Replacement with Favorable Regulatory Path and 2026 Inflection Point
TIPRANKS  ·  03-20 01:35
Larimar Therapeutics: Undervalued First-in-Class Frataxin Replacement with Favorable Regulatory Path and 2026 Inflection Point

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--